However, some patients still had abnormal serum aminotransferase levels even if they has achieved undetectable HBV DNA (or complete viral response, CVR) for a long time, the reasons of which hasn’t been studied. This research aimed to define the risk factors correlated with biochemical abnormality after CVR in patients treated with NAs. Methods: selleck products 388 chronically
HBV infected patients ongoing naive NAs therapy, who achieved undetectable serum HBV DNA (<20IU/ml) during Jan. 2006 and Feb. 2014, were retro- and prospectively followed. Patients were divided into two groups: patients with normal ALT (n=298) and with abnormal ALT (n=90) (defined as serum ALT >40U/L in male or >35U/L in female at least twice consecutively with a interval of 1-3 months after achieving undetectable HBV DNA). Multivariate logistic regression analysis was used to
screen the risk factors of ALT abnormality. Results: The median follow-up duration was 42.0 months. The demographic characteristics http://www.selleckchem.com/products/SB-203580.html (gender, age, family history of HBV infection/cirrhosis/ hepatocellular carcinoma (HCC), alcohol abuse history, et al.), baseline data (HBeAg positivity, ALT, AST, HBV DNA level, et al), antiviral agents, rates of viral breakthrough or optimized therapy and progressing to HCC during therapy, were comparable in both groups. The body mass index (BMI) (24.1 ±3.5 vs. 22.5±3.2 kg/m2, t=4.165, P<0.001), rates of preexisting cirrhosis (45.6 %vs. 27.2%, x2=10.826, P=0.001) and HBeAg seroconversion medchemexpress (58.1 %(25/43) vs. 39.2 %(49/125), x2=5.754, P=0.016) in patients with abnormal ALT levels were higher than patients with normal ALT levels. Multivariate logistic regression analysis showed preexisting cirrhosis (OR=2.472,
95 %CI=1.424-4.292, P=0.001), higher BMI (OR=1.170, 95%CI = 1.077-1.271, P<0.001), and HBV DNA levels at year 1 (OR=1.727, 95 %CI=1.017-2.933, P=0.043) rather than baseline HBV DNA levels, antiviral agents or alcohol intake, were independent risk factors for ALT abnormality after achieving undetectable HBV DNA. Conclusion: Patients with preexisting cirrhosis, higher BMI and HBV DNA levels at year 1 were more likely to show abnormal ALT levels even after achieving undetectable HBV DNA during NAs therapy. Disclosures: Yuankai Wu – Grant/Research Support: Bristol-Myers Squibb Company The following people have nothing to disclose: Yusheng Jie, Xiangyong Li, Guoli Lin, Shu-ru Chen, Xin-Hua Li, Hong Shi, Fangji Yang, Min Zhang, Mingxing Huang, Yunlong Ao, Yihua Pang, Yutian Chong Background and aims: Data are limited on tenofovir (TDF) treatment discontinuation after long-term viral suppression in HBeAg-negative patients. This study investigates whether TDF discontinuation in this scenario is associated with a low rate of virologic relapse.